Who participates in a randomized trial of mindfulness-based stress reduction (MBSR) after breast cancer? A study of factors associated with enrollment among Danish breast cancer patients

2012 ◽  
Vol 22 (5) ◽  
pp. 1180-1185 ◽  
Author(s):  
Hanne Würtzen ◽  
Susanne Oksbjerg Dalton ◽  
Klaus Kaae Andersen ◽  
Peter Elsass ◽  
Henrik Lavlund Flyger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Stress Reduction ◽  
Breast Cancer Patients ◽  
Factors Associated ◽  
Mindfulness Based Stress Reduction

scholarly journals Effect of mindfulness-based stress reduction on sleep quality: Results of a randomized trial among Danish breast cancer patients

2013 ◽  
Vol 52 (2) ◽  
pp. 336-344 ◽  
Author(s):  
Signe R. Andersen ◽  
Hanne Würtzen ◽  
Marianne Steding-Jessen ◽  
Jane Christensen ◽  
Klaus K. Andersen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sleep Quality ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Stress Reduction ◽  
Breast Cancer Patients ◽  
Mindfulness Based Stress Reduction

scholarly journals A qualitative study on mindfulness-based stress reduction for breast cancer patients: how women experience participating with fellow patients

2015 ◽  
Vol 24 (4) ◽  
pp. 1813-1820 ◽  
Author(s):  
Melanie P. J. Schellekens ◽  
Ellen T. M. Jansen ◽  
Heidi H. M. A. Willemse ◽  
Hanneke W. M. van Laarhoven ◽  
Judith B. Prins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Qualitative Study ◽  
Cancer Patients ◽  
Stress Reduction ◽  
Breast Cancer Patients ◽  
Mindfulness Based Stress Reduction

scholarly journals Mindfulness-based stress reduction for breast cancer patients: a mixed method study on what patients experience as a suitable stage to participate

2017 ◽  
Vol 25 (10) ◽  
pp. 3067-3074 ◽  
Author(s):  
Else M. Bisseling ◽  
Melanie P.J. Schellekens ◽  
Ellen T.M. Jansen ◽  
Hanneke W.M. van Laarhoven ◽  
Judith B. Prins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Stress Reduction ◽  
Mixed Method ◽  
Mixed Method Study ◽  
Breast Cancer Patients ◽  
Mindfulness Based Stress Reduction ◽  
Patients Experience

Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters

2011 ◽  
Vol 35 (1) ◽  
pp. 86-94 ◽  
Author(s):  
Cecile A. Lengacher ◽  
Richard R. Reich ◽  
Janice Post-White ◽  
Manolete Moscoso ◽  
Melissa M. Shelton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Stress Reduction ◽  
Post Treatment ◽  
Symptom Clusters ◽  
Breast Cancer Patients ◽  
Mindfulness Based Stress Reduction

scholarly journals An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study

2021 ◽  
Vol 11 (3) ◽  
pp. 484-493
Author(s):  
Jukapun Yoodee ◽  
Aumkhae Sookprasert ◽  
Phitjira Sanguanboonyaphong ◽  
Suthan Chanthawong ◽  
Manit Seateaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Factors Associated ◽  
Palliative Intent ◽  
Increased Risk

Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence and factors associated with HF in breast cancer patients treated with anthracyclines with or without trastuzumab. A retrospective cohort study was performed in patients with breast cancer who were treated with anthracyclines with or without trastuzumab between 1 January 2014 and 31 December 2018. The primary outcome was the incidence of HF. The secondary outcome was the risk factors associated with HF by using the univariable and multivariable cox-proportional hazard model. A total of 475 breast cancer patients were enrolled with a median follow-up time of 2.88 years (interquartile range (IQR), 1.59–3.93). The incidence of HF was 3.2%, corresponding to an incidence rate of 11.1 per 1000 person-years. The increased risk of HF was seen in patients receiving a combination of anthracycline and trastuzumab therapy, patients treated with radiotherapy or palliative-intent chemotherapy, and baseline left ventricular ejection fraction <65%, respectively. There were no statistically significant differences in other risk factors for HF, such as age, cardiovascular comorbidities, and cumulative doxorubicin dose. In conclusion, the incidence of HF was consistently high in patients receiving combination anthracyclines trastuzumab regimens. A reduced baseline left ventricular ejection fraction, radiotherapy, and palliative-intent chemotherapy were associated with an increased risk of HF. Intensive cardiac monitoring in breast cancer patients with an increased risk of HF should be advised to prevent undesired cardiac outcomes.

Sign in / Sign up

Export Citation Format

Share Document